Therapy News and Research

RSS

Use of testosterone therapy after angiography associated with increased risk of death

Among a group of men who underwent coronary angiography and had a low serum testosterone level, the use of testosterone therapy was associated with increased risk of death, heart attack, or ischemic stroke, according to a study in the November 6 issue of JAMA.

6 Nov 2013

New drug combination therapy effectively kills cancer cells

Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.

6 Nov 2013

New treatment option for patients with most difficult-to-treat forms of hepatitis C

A novel single-pill combination drug could present a new treatment option for patients with the most difficult-to-treat forms of hepatitis C, according to the results of a Phase 2 trial, published in The Lancet.

6 Nov 2013

Endocrine Society publishes Clinical Practice Guideline on diabetes and pregnancy

The Endocrine Society today issued a Clinical Practice Guideline to help health care professionals provide the best care to pregnant women who have diabetes.

6 Nov 2013

Physicians' Education Resource to host 11th Annual School of Breast Oncology in Atlanta, GA

The go-to source for excellence in continuing medical education, Physicians' Education Resource®, LLC, will host the 11th Annual School of Breast Oncology November 7-10 at the Emory University Conference Center in Atlanta, GA.

6 Nov 2013

Tel Aviv University researchers study long-term effects of torture on human pain system

Israeli soldiers captured during the 1973 Yom Kippur War were subjected to brutal torture in Egypt and Syria. Held alone in tiny, filthy spaces for weeks or months, sometimes handcuffed and blindfolded, they suffered severe beatings, burns, electric shocks, starvation, and worse.

6 Nov 2013

Scientists investigate combined action of two different compounds against CML

Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek's group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang Jahnke and colleagues from Novartis, has investigated the combined action of two different compounds against this form of leukemia.

6 Nov 2013

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.

6 Nov 2013

One Lambda gets CE mark approval in Europe for C1qScreen assay

One Lambda Inc., part of Thermo Fisher Scientific and a leading producer of in vitro diagnostic products for the human leukocyte antigen transplant community, has received CE mark approval in Europe for its C1qScreen assay.

6 Nov 2013

Depomed reports financial results for third quarter 2013

Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.

6 Nov 2013

Duke Cancer Institute is one among 41 cancer centers in U.S to hold distinction

Established and designated by the National Cancer Institute as one of eight original comprehensive cancer centers in 1973, the Duke Cancer Institute (DCI) is now among just 41 cancer centers in the United States to hold that distinction.

6 Nov 2013

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

5 Nov 2013

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin, a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis.

5 Nov 2013

Endocrine Society announces winners of organization's prestigious 2014 Laureate Awards

The Endocrine Society today announced it has selected 15 accomplished endocrinologists as winners of the organization's prestigious 2014 Laureate Awards.

5 Nov 2013

Weight loss surgery: The most effective weapon for obese people in the battle against diabetes

Noted bariatric surgeon Michael Feiz, M.D., F.A.C.S., believes that there's no time like American Diabetes Month to point out that weight loss surgery is the most effective weapon obese people have in the battle against diabetes.

5 Nov 2013

Insomnia concerns go unaddressed in heart failure patients

The impact of insomnia on health and function is a major concern for patients with heart failure, qualitative and quantitative research shows.

5 Nov 2013

Metacognitive training complements antipsychotic therapy

Metacognitive training may benefit patients with schizophrenia who only partially respond to antipsychotic treatment, study findings show.

5 Nov 2013

Financial interests ‘driving IMRT uptake for prostate cancer’

A study suggests that the recent rapid uptake of intensity-modulated radiotherapy for prostate cancer in the USA has been driven by urologists with financial conflicts of interest.

5 Nov 2013

Health anxiety therapies: an interview with Professor Peter Tyrer, Imperial College, London

Health anxiety is a relatively new diagnosis and has not been adopted fully. The nearest approximation and formal classification systems is ‘illness anxiety’ as diagnosed in DSM-5, published in May 2013 (DSM-5, American Psychiatric Association, p.315).

5 Nov 2013

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.

5 Nov 2013

Therapy News and Research

Use of testosterone therapy after angiography associated with increased risk of death

New drug combination therapy effectively kills cancer cells

New treatment option for patients with most difficult-to-treat forms of hepatitis C

Endocrine Society publishes Clinical Practice Guideline on diabetes and pregnancy

Physicians' Education Resource to host 11th Annual School of Breast Oncology in Atlanta, GA

Tel Aviv University researchers study long-term effects of torture on human pain system

Scientists investigate combined action of two different compounds against CML

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

One Lambda gets CE mark approval in Europe for C1qScreen assay

Depomed reports financial results for third quarter 2013

Duke Cancer Institute is one among 41 cancer centers in U.S to hold distinction

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Endocrine Society announces winners of organization's prestigious 2014 Laureate Awards

Weight loss surgery: The most effective weapon for obese people in the battle against diabetes

Insomnia concerns go unaddressed in heart failure patients

Metacognitive training complements antipsychotic therapy

Financial interests ‘driving IMRT uptake for prostate cancer’

Health anxiety therapies: an interview with Professor Peter Tyrer, Imperial College, London

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News